Access to anti-retroviral drugs, female in Spain

Spain: Access to anti-retroviral drugs, female was 89.0% in 2022. ▲ Rising

Latest (2022)
89.0%
Change on year
up 3.5%
World rank
35th
of 141 countries
All-time high
89.0%
in 2022
All-time low
32.0%
in 2000
Years of data
23
2000–2022

Access to anti-retroviral drugs, female in Spain, 2000–2022

0204060802000201120222000: 32 %2001: 39 %2002: 44 %2003: 49 %2004: 54 %2005: 59 %2006: 64 %2007: 68 %2008: 72 %2009: 77 %2010: 78 %2011: 79 %2012: 80 %2013: 82 %2014: 83 %2015: 85 %2016: 86 %2017: 88 %2018: 87 %2019: 87 %2020: 86 %2021: 86 %2022: 89 %

Source: UNAIDS estimates. Measured in %.

Analysis

Spain recorded 89.0% for access to anti-retroviral drugs, female in 2022. That is the highest value across all 23 years on record.

The figure is up 3.5% on the previous year and up 11.2% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Spain peaked at 89.0% in 2022 and was at its lowest, 32.0%, in 2000.

Spain ranks 35th of 141 countries on this measure, in the top quarter.

The long-run direction has been consistently rising across the 23 years of available data.

Access to anti-retroviral drugs, female in Spain, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Spain, 2000 to 2022.
Year % Change
2000 32.0%
2001 39.0% +21.9%
2002 44.0% +12.8%
2003 49.0% +11.4%
2004 54.0% +10.2%
2005 59.0% +9.3%
2006 64.0% +8.5%
2007 68.0% +6.2%
2008 72.0% +5.9%
2009 77.0% +6.9%
2010 78.0% +1.3%
2011 79.0% +1.3%
2012 80.0% +1.3%
2013 82.0% +2.5%
2014 83.0% +1.2%
2015 85.0% +2.4%
2016 86.0% +1.2%
2017 88.0% +2.3%
2018 87.0% -1.1%
2019 87.0% +0.0%
2020 86.0% -1.1%
2021 86.0% +0.0%
2022 89.0% +3.5%

Averages by decade

DecadeAverage LowestHighest Years
2000s 55.8% 32.0% 77.0% 10
2010s 83.5% 78.0% 88.0% 10
2020s 87.0% 86.0% 89.0% 3

Countries ranked near Spain

  1. 35 Argentina 89.0% compare
  2. 35 Belgium 89.0% compare
  3. 35 Cambodia 89.0% compare
  4. 35 Croatia 89.0% compare
  5. 35 Guinea-Bissau 89.0% compare
  6. 35 Italy 89.0% compare
  7. 35 Netherlands 89.0% compare
  8. 35 Nigeria 89.0% compare

See the full ranking of 160 places →

More gender data for Spain

All data for Spain →

Frequently asked questions

What is access to anti-retroviral drugs, female in Spain?
Access to anti-retroviral drugs, female in Spain was 89.0% in 2022, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Spain?
The highest recorded value was 89.0% in 2022.
What is the lowest access to anti-retroviral drugs, female recorded in Spain?
The lowest recorded value was 32.0% in 2000.
How does Spain rank for access to anti-retroviral drugs, female?
Spain ranks 35th out of 141 countries with data for 2022.
Is access to anti-retroviral drugs, female rising or falling in Spain?
Over the last ten years it is up 11.2%. The long-run trend across the full record is rising.
Where does this Spain data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 23 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Spain. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/spain/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/spain/">Access to anti-retroviral drugs, female in Spain</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.